www.HIVdent.org

 

Research News

 
PrEP at IAS 2017 / IAS Coverage News Updates
Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - (08/07/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark (08/07/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM  - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits -  (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP -  (07/28/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus -  (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
“Super Receptor” May Hold Key to HIV Cure Research
POZ \ June 19, 2018
CD4+ T cell–mediated HLA class II cross-restriction in HIV controllers
HIV Functional Cure That Controls Virus, Destroys Infected Cells In Mice Created by Scientists
Newsweek | June 16, 2018
Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients
ASM Microbe 2018, June 7-11, 2018, Atlanta
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
Nature Medicine June 4 2018
Have We Just Gotten Closer To A Cure For HIV?
Men's Health | May 8, 2018
NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV ...
National Institutes of Health | May 7, 2018
Scientists invent universal antibody drug against HIV, AIDS
P.M. News | April 26, 2018
Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus
NIH | April 16, 2018
NIH researchers use genomics to set squamous cell carcinomas apart from other cancers
NIH | April 5, 2018
High uptake and use of vaginal ring for HIV prevention observed in open-label study
NIH | March 6, 2018
Next Steps on Refining the NIH HIV Clinical Research Enterprise - view meeting webcast
NYU Dentistry Develops Saliva Test for Zika
Washington Square News | March 1, 2018
Slight Changes to Broadly Neutralizing HIV Antibody Yield Great Dividends
HIV.gov | February 23, 2018
All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs
Endpoints News | February 22, 2018
Case Western Reserve and Sangamo Therapeutics announce $11 million NIH grant for study of gene-edited T cells for the viral eradication of HIV
the daily | February 22, 2018
Novel drug delivery system with potential to reduce rates of HIV announced
Jamaica Observer | February 18, 2018
Research study gathers real world insights from people living with HIV through mobile devices
ViiV Healthcare, Research Triangle Park, 17th January 2018
Frederick National Laboratory researchers identify why some patients fight HIV better than others
Frederick News Post | February 17, 2018
Exploiting immune cell metabolic machinery for functional HIV cure and the prevention of inflammaging
F1000Research
Progress toward an HIV cure in annual special issue of AIDS Research & Human Retroviruses
Medical Xpress | January 25, 2018
Simple blood test detects eight different kinds of cancer
Nature | January 18, 2018
Benefits of HIV Research Go Beyond HIV
HIV.gov | January 18, 2018
Powerful HIV-neutralizing response possible in most people, study by San Diego researchers finds
The San Diego Union-Tribune | January 14, 2018
The coming of age of gene therapy: A review of the past and path forward
NIH | January 12, 2018
NIAID Study Supports Use of Short-Term HIV Treatment Interruption in Clinical Trials
NIH |  January 11, 2018
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose
aidsmap | January 9, 2018
Genetically modifying stem cells to produce HIV-fighting blood may someday be possible, according to a new paper published in PLOS Pathogens on Tuesday
PLOS Pathogens | December 28, 2017
CAR-Engineered Blood Stem Cells Offer New Hope for Long-Term HIV Gene Therapy
Genetic Engineering & Biotechnology News | December 29, 2017
Gene therapy using CAR T-cells could provide long-term protection against HIV
EurekAlert | December 28, 2017
The HIV co-receptor CCR5 regulates osteoclast function
Nat Commun. 2017 Dec 20;8(1):2226. doi: 10.1038/s41467-017-02368-5
People with high viral load most likely to report sex that could pass on HIV
aidsmap | December 18, 2017
NIH Statement on World AIDS Day
NIH | December 1, 2017
Gene editing shows promise as curative treatment for HIV
ModernMedicine | December 1, 2017
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
European Society for Medical Oncology | November 30, 2017
Study to Test Efficacy, Safety of Injectable Cabotegravir Compared With Daily Oral PrEP
Infection Control Today | November 30, 2017
NIH and Partners Launch HIV Vaccine Efficacy Study
NIAID | November 30, 2017
Combination HIV Prevention Reduces New Infections by 42 Percent in Ugandan District
NIH | November 29, 2017
Four big insights into HIV/AIDS that provide hope of finding a vaccine
Medical Xpress | November 24, 2017
New findings to help HIV scientists establish 'template' for potent antibodies
Medical Xpress | November 21, 2017
The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro
AASLD 2017 Oct 20-24
US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials
Clinical Infectious Diseases | 15 July 2017
Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection
Hum Vaccin Immunother. 2016 May 3;12(5):1295-9. doi: 10.1080/21645515.2015.1121336. Epub 2016 Jan 11
A scientific breakthrough offers hope for an AIDS vaccine
CNBC | October 19, 2017

Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research

NATAP | October 16, 2017

Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

October 10, 2017

UCLA receives $5 million grant for sharing research on AIDS and substance abuse

UCLA Newsroom | September 28, 2017

Three-in-One Antibody Protects Monkeys from HIV-like Virus

NIH | September 20, 2017

Nanoparticles awaken immune cells to fight cancer

Science | Jan. 5, 2017

New HIV Weapon: A Cancer Drug That Kills HIV-Infected Cells

Wall Street Pit | August 30, 2017

NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks with HIV

NIH/NIAID | August 30, 2017

First CAR T-Cell 'Living Drug' Approved by FDA 

Medscape | August 30, 2017

NIH herpesvirus study in mice leads to discovery of potential broad-spectrum antiviral

NIH | August 15, 2017

Why curing HIV may be like curing cancer – and may be as difficult

aidsmap | August 3, 2017

VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

aidsmap | August 2, 2017
HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights
Volume: 33 Issue 8: August 1, 2017
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations
Volume: 33 Issue 8: August 1, 2017

France's next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic

aidsmap | July 28, 2017
Long-Acting Rilpivirine Suppresses Replication in Rectal Explants
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris

Long-acting cabotegravir injection shows promise for HIV prevention

aidsmap | July 27, 2017
No HIV Infections With Generic TDF/FTC PrEP in Large London Group
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris

Oral PrEP Drug Truvada, Dapivirine Vaginal Ring Safe, Acceptable HIV Prevention Methods…

Kaiser Family Foundation | July 26, 2017

Experimental HIV vaccine regimen is well-tolerated, elicits immune responses

aidsmap | July 24, 2017

Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077

9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris

ACTG A5353: A pilot study of  dolutegravir (DTG) + lamivudine (3TC)  for initial treatment of  HIV-1-infected participants with  HIV-1 RNA <500,000 copies/ml

9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris

Evidence of production of HIV-1 proteins from “defective” HIV-1 proviruses in vivo: Implication for persistent immune activation and HIV-1 pathogenesis

9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
A global survey of HIV-positive people's attitudes towards cure research
HIV Medicine Feb 2017

Clinical Trial Results Support Further Development of Candidate HIV Vaccines

NIH | July 24, 2017

NIH-supported scientists elicit broadly neutralizing antibodies to HIV in calves

NIH | July 20, 2017

Finding May Help Explain Persistent Immune Activation During Suppressive HIV Treatment

July 18, 2016

Proton pump inhibitors may blunt CD4 cell gains, cause immune activation, in people with HIV

aidsmap | July 13, 2014

Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China

AIDS Behav. 2017 Jul 13. doi: 10.1007/s10461-017-1845-z

HIV hijacks surface molecule to invade cell
NIH News | July 12, 2017

HIV-AIDS Cure News: Researchers Find Asian Plant With Potential HIV-Curing Compound

Christian Post | July 9, 2017

HIV vaccine boost generates higher immune response 6 to 8 years later

Healio | July 2, 2017

NIH Funds NYC Center for AIDS Research

PR Newswire (press release) | June 9, 2017

Federal Funding for HIV/AIDS

AIDS.gov blog (blog)

Scientists Jump Hurdle in HIV Vaccine Design

MilTech | May 26, 2017
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women

NIH Statement on HIV Vaccine Awareness Day

AIDS.gov blog (blog) | May 18, 2017

HIV/AIDS Cure Latest News 2017: Gene Editing Found as an Effective Cure to HIV

Christian Post | May 9, 2017

Researchers use gene editing to eliminate HIV infection in mice

CBS News | May 3, 2017

UNC researchers make big discovery in HIV/AIDS research

WTVD-TV | May 1, 2017

HIV, AIDS Cure News 2017: HIV Can Hide in Macrophages, With Dire Implications on Search of Cure

Christian Post | April 22, 2017

NIDA awards three researchers $2.5 million each for HIV/AIDS projects

Healio | Apr 8, 2017
UNC ressearchers developing injectable implant for long-acting HIV/AIDS prevention
Healio | April 1, 2017

UNC to Create and Test Injectable Long-Acting Implant to Prevent HIV/AIDS

Infection Control Today | Mar 24, 2017

Participants needed for research study on HIV and aging

Rural Center for AIDS/STD Prevention | Mar 22, 2017

Early antibody therapy can induce long-lasting immunity to SHIV / Dual Antibody Therapy

NATAP | March 15, 2017

Nanomedicine provides HIV treatment alternative

Healio | March 1, 2017

New nano approach could cut dose of leading HIV treatment in half

ScienceBlog.com | Feb 24, 2017

New research on using CRISPR/Cas9 to treat HIV
AIDS: Feb 20 2017

NIH Research Helps Explain How Antibody Treatment Led to Sustained Remission of HIV-Like Virus
NIH | February 15, 2017

Highlights from the Third Biennial Strategies for an HIV Cure Meeting

National Institute of Allergy and Infectious Diseases | January, 2017

Clinical Trials of HIV Cure: Where have we been? Where are we going? talk by Dan Kuriztkes

Implants and injectables: PrEP in the future

aidsmap | Jan 13, 2017

A New HIV Therapy uses DNA and Antibodies to fight Viral Reservoirs

labiotech.eu | Jan 2017

Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research

Business Wire (press release) | Jan 10, 2017

Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research

Business Wire | Jan 10, 2017

Under-the-skin implant which releases daily PrEP dose could slash HIV infection rates

Daily Mail | Jan 4, 2017

Past Research News Archives